To read the full story, subscribe or sign in.

Ascletis signs deal for 3-V Biosciences' NASH treatment

Feb. 20, 2019

HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.

BioWorld Asia

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for April 9.

Somalogic to merge with CM Life Sciences II SPAC, as trendy IPO path continues

BioWorld MedTech

Somalogic Inc. has agreed to go public via a merger with blank-check company CM Life Sciences II. Upon closing, CMLS II – a special purpose acquisition company...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for April 9.

Global cases rise, but more weapons advance to combat COVID-19

BioWorld

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.